Experience with new chemotherapeutic agents in non-small cell lung cancer

Chest

Volumn 113, Issue 1 SUPPL., 1998, Pages 32S-39S

  Natale, Ronald B ^a,b  

^a Department of Hematology Oncology Cedars Sinai Comprehensive Cancer Center   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; PYRIMIDINE DERIVATIVE; TAXANE DERIVATIVE;

ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; VOMITING;

EID: 0031985596     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.1_Supplement.32S     Document Type: Article

References (74)

1. Cancer facts and figures - 1993. Atlanta: American Cancer Society, 1993; 10
2. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327:1434-41
3. Ihde DC. Non-small cell lung cancer: I. Biology, diagnosis and staging. Curr Probl Cancer 1991; 15:61-104
4. Gralla RJ, Kriss MG. Chemotherapy in non-small cell lung cancer: results of recent trials. Semin Oncol 1988; 15(suppl 4):205-08
5. Casper ES, Gralla RJ, Kelsen DP, et al. Phase II study of high-dose cis-dichlorodiammine-platinum (II) in the treatment of non-small cell lung cancer. Cancer Treat Rep 1979; 63:2107-09
6. De Jager, Longeval I, Klastersky J. High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of EORTC Lung Cancer Working Party (Belgium). Cancer Treat Rep 1980; 64:1341-46
7. Bunn PA Jr. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16(suppl): 10-21
8. Gralla RJ, Raphael BG, Golbey RB, et al. Phase II evaluation of vindesine (VDS) monochemotherapy for non-small cell lung cancer: a report of 45 cases. Cancer Treat Rep 1982; 66:1409-11
9. Furnas BE, Williams SD, Einhorn LH, et al. Vindesine: an effective agent in the treatment of non-small cell lung cancer: a report of 45 cases. Cancer Treat Rep 1982; 66:1709-11
10. Leudke SL, Luedke DW, Petruska P, et al. A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer. Cancer 1983; 57:778-82
11. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991; 14:115-19
12. O'Rourke M, Crawford J, Schiller J, et al. Survival advantage for patients with stage IV NSCLC with single agent Navelbine in a randomized controlled trial [abstract]. Proc Am Soc Clin Oncol 1993; 12:342
13. Depierre A, Lebeau B, Chastang C, et al. Result of a phase II randomized study of vinorelbine (V) versus vinorelbine-cisplatin (VP) in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1993; 12:340
14. Balbiana L, Coppola F, Blajman C, et al. Navelbine (NVB) vs NVB plus cisplatin in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1993; 12:352
15. Kris MG. Mitomycin in combination chemotherapy regimens for patients with advanced non-small cell lung cancer. In: Gralla RJ, Einhorn LG, eds. Treatment and prevention of small cell and non-small cell lung cancer. New York: Royal Society of Medicine, 1989; 73-82
16. Drings P. Ifosfamide in the treatment of bronchial carcinoma. In: Brade WB, Nagel EA, Seeber S, eds. Ifosfamide in tumor therapy. New York: Karger, 1987; 294-318
17. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-41
18. Pignon JP, Stewart LA, Souhami RL, et al. A meta-analysis using individual patient data from randomized clinical trials of chemotherapy in non-small cell lung cancer: survival in the locally advanced setting [abstract]. Proc Am Soc Clin Oncol 1994; 13:A1109
19. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323:940-45
20. Dillman RO, Seagren S, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy vs RT alone in stage III non-small cell lung cancer (NSCLC): five-year follow-up of CALGB84-33 [abstract]. Proc Am Soc Clin Oncol 1993; 12:A1092
21. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung carcinoma. N Engl J Med 1992; 326:524-30
22. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effects of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma [letter]. J Natl Cancer Inst 1992; 84:58
23. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4:702-09
24. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07801. J Clin Oncol 1990; 8:1556-62
25. Bonomi PD, Finkelstein DM, Ruckdesehel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study by the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602-13
26. Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of cis-diammine-1, -1-cyclobutane dicarboxylate platinum (H) in patients with normal and impaired renal function. Cancer Res 1984; 44:1693-97
27. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 1984; 44:5432-38
28. Calvert AH, Newekk DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748-56
29. Feigal EG, Christian M, Cheson B, et al. New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 1993; 20:185-201
30. Rowinsky EK, Cazenave LA, Donehower RC, et al. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247-59
31. Chabner BA. PPO updates (vol 5, No. 9). Philadelphia: JB Lippincott, September 1991
32. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, Merbarone and Piroxantrone in stage IV NSCLC: the ECOG results. J Natl Cancer Inst 1993; 85:388-94
33. Murphy WK, Fossella FV, Winn RJ, et al. A phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85:384-88
34. Swenerton K, Eisenhauer E, Bokkel Hunink WT, et al. Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group [abstract]. Proc Am Soc Clin Oncol 1993; 12:259
35. Gatzemeier U, Heckmayer M, Neuhauss R, et al. Phase II study with paclitaxel for the treatment of advanced inoperable NSCLC. Lung Cancer 1995; 12:101-06
36. Hainsworth JD, Thompson DS, Spigel SC, et al. Paclitaxel by 1-hour infusion in the treatment of stage IV or relapsed non-small cell lung cancer (NSCLC) [abstract 116]. Proc Am Soc Clin Oncol 1995; 14:364
37. Forastiere AA, Rosinsky E, Chaudhury V, et al. Phase I trial of taxol (T) and cisplatin (C) + GCSF in solid tumors [abstract]. Proc Am Soc Clin Oncol 1992; 11:117
38. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide-cisplatin versus Taxol with eisplatin-G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1996; 15:382
39. Paul DM, Johnson DH, Hande KR, et al. Carboplatin and Taxol: a well-tolerated regimen for advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: A1181
40. Langer CJ, Leighton J, Comis R, et al. Taxol and carboplatin in combination in stage IV and IIIB non-small cell lung cancer: a phase II trial [abstract]. Proc Am Soc Clin Oncol 1994; 13:A1181
41. Langer CJ, Leighton J, Comis R, et al. Paclitaxel (Taxol) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC): toxicity, response and survival update [abstract 1080]. Proc Am Soc Clin Oncol 1995; 14:355
42. Vafai D, Israel V, Zaretsky S, et al. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1996; 23(suppl 6):51-54
43. Kearns CM, Belani CP, Erkman K, et al. Reduced platelet toxicity with combination carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin-associated thrombocytopenia [Abstract]. Proc Am Soc Clin Oncol 1995; 14:170
44. Hertel LW, Kroin JS, Misner JW, et al. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 1988; 53:2406-09
45. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50:4417-22
46. Abbruzzese JL, Grunewald R, Weeks EA, et al. Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-98
47. Fosella FV, Lippman S, Pang A, et al. Phase I/II study of gemcitabine by 30 minute weekly intravenous infusion X 3 weeks every 4 weeks for non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12:326
48. Abbruzzese JL, Pazdur R, Ajani J, et al. A Phase I trial of gemcitabine in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1991; 10:456
49. Casper ES, Green MR, Brown DP, et al. Phase II trial of gemcitabine in patients with pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1991; 10:440
50. Tonato M. Gemcitabine safety overview. In: Gemcitabine, novel combination of efficacy and tolerability. Proc Eur Cong Clin Oncol 7 Satellite Symposium. Jerusalem, Israel: November 1993; 14-16
51. Anderson H, Thatcher N, Walling J, et al. Gemcitabine and palliation of symptoms in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13:367
52. Negoro S, Fukuoka M, Kurita Y, et al. Results of phase I studies of gemcitabine in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1994; 13:367
53. Shepherd FA, Gatzemeier U, Gotfried M, et al. An extended phase II study of gemcitabine in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1993; 12:330
54. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1535-40
55. Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al. Schedule dependency of the synergism between the combination of cisplatin and gemcitabine in resistant A2780 human ovarian cancer cell lines [abstract]. Ann Oncol 1994; 5(suppl):82
56. Braakhuis BJ, Ruiz van Hapren WT, Bergman AM, et al. Preclinical in vivo evaluation of the combination of 2′,2′-difluorodeoxycytidine and cisplatin [abstract]. Ann Oncol 1994; 5(suppl):82
57. Data on file. 1995 Indianapolis: Eli Lilly
58. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10(1-piperidino)-1-piperidinocarbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47:5944-47
59. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase. Int J Biol Chem 1985; 260:14873-78
60. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48:1722-26
61. Muggia FM, Creaven PJ, Hansen JJ, et al. Phase I trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56:515-21
62. Yokokura T, Sawada S, Nokata K, et al. Antileukemic activity of new camptothecin derivatives. Proceedings of the Japanese Cancer Association 40th Annual Meeting, Sapporo, Japan, 1981; 228
63. Yokokura T, Furuta T, Sawada S, et al. Antitumor activity of newly synthesized, lactone ring-closed and water-soluble camptothecin derivative in mice. Proceedings of the Japanese Cancer Association 43rd Annual Meeting, Fukuoka, Japan, 1984; 261
64. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991; 83:1164-68
65. Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 1994; 12:90-96
66. Fukuoka M, Negoro S, Niitani H, et al. A phase I study of weekly administration of CPT-11 in lung cancer. Jpn J Cancer Chemother 1990; 17:993-97
67. Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991; 18:607-12
68. Niita T, Takada M, Hirashima T, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer [abstract 1227]. Proc Am Assoc Cancer Res 1993; 34:206
69. Mori K, Suga U, Kishiro I, et al. A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer [abstract 1234]. Proc Am Soc Clin Oncol 1994; 13:366
70. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68:777-82
71. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991; 18:1013-19
72. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin lor advanced non-small cell lung cancer. J Clin Oncol 1992; 10:1775-80
73. Nakagawa K, Fukuoka M, Niitani H, et al. Phase II study of irinotecan (CPT-11), and cisplatin in patients with advanced non-small cell lung cancer [abstract 1104]. Proc Am Soc Clin Oncol 1993; 12:332
74. Shinkai T, Arioka H, Kunikane H, et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 1994; 54:2636-42